Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 625, Issue 1-3, Pages 41-54Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2009.09.067
Keywords
Immunotherapy; Cancer; Monoclonal antibody; Cell-based therapy; Toll-like receptors
Categories
Funding
- Centers of Research Excellence [CA06927]
- National Cancer Institute (NCI)
- National Institutes of Health
- Fox Chase Cancer Center
- [CA083859]
- [CA100226]
Ask authors/readers for more resources
Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available